Plat

(redirected from tissue plasminogen activator)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Related to tissue plasminogen activator: streptokinase

Plat

A map of a town or a section of land that has been subdivided into lots showing the location and boundaries of individual parcels with the streets, alleys, easements, and rights of use over the land of another.

A plat is usually drawn to scale.

See: intertwine, land, plot

PLAT. A map of a piece of land, in which are marked the courses and distances of the different lines, and the quantity of land it contains.
     2. Such a plat;nay be given in evidence in ascertaining the position of the land, and what is included, and may serve to settle the figure of a survey, and correct mistakes. 5 Monr. 160. See 17 Mass. 211; 5 Greenl. 219; 7 Greenl, 61; 4 Wheat. 444; 14 Mass. 149.

References in periodicals archive ?
Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients?
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomized controlled trial.
Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli.
Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
Spontaneous hepatic hemorrhage following treatment with tissue plasminogen activator.
The team obtained MR scans immediately before and approximately four hours after administration of intravenous tissue plasminogen activator, or tPA, a drug that dissolves blood clots.
Unless a high level of tissue plasminogen activator (TPA) in relation to plasminogen activator inhibitor-1 (PAI-1) can break up the mass, conditions become ripe for uniquely equipped fibroblasts to proliferate and amass at the site of injury.
The two agents, which were launched in Japan in May 1991, are based on a recombinant tissue plasminogen activator developed by US firm Genentech.
Recombinant tissue plasminogen activator for the treatment of spontaneous adult intraventricular hemorrhage.
Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.
Fibrinolysis starts at the site of initial injury, where damaged tissues release tissue plasminogen activator (t-PA).